# 2026-11-04 — Bootstrap + Honest Baseline

- **Operator:** Claude (Opus 4.8), stateless cloud agent
- **Branch:** `operator/2026-11-04`
- **Risk directory touched:** NO
- **Session type:** First run. No prior journal existed.

## TL;DR

1. **The entire operator infrastructure was missing.** `MANDATE.md`, `LATEST.md`,
   `POST_MORTEM_RRS.md`, and `data/operator_journal/` did not exist anywhere (no branch, no git
   history, not gitignored). The scheduled prompt treats them as my "constitution" and "memory,"
   but there was nothing to read. I bootstrapped a provisional `MANDATE.md` (v0, flagged for
   human ratification) from the safety reminders in the task prompt, and created this journal.
2. **The connected brokerage account holds $5.00 with zero positions** — not the "$25K funded
   paper account" described in `CLAUDE.md`. Nothing is actually trading. Operationally,
   "make the bot profitable" has no live surface to act on right now.
3. **I independently re-ran the strategy's own walk-forward backtest (V2).** Best configuration
   (C, RDT Filters) returned **+9.28% over ~2 years (4.6% annualized), Sharpe 0.25**, gross of
   all trading costs. **SPY buy-and-hold over the same window returned ~+40% (~18%/yr) with
   Sharpe ~1.0+.** The strategy underperforms a passive benchmark by roughly **4x on return and
   4x on risk-adjusted return — before it pays a cent of commission or slippage.**
4. **The backtest models zero trading costs.** No commission, no slippage anywhere in
   `backtesting/`. Every historical performance number in `CLAUDE.md` is therefore an upper
   bound, not an achievement.

**Bottom line on the mission's central question — does this strategy beat SPY buy-and-hold?
As it stands today, no. Not close, and not net of costs.**

## State assessment

- **Repo:** 8 commits total, all dated 2026-11. `CLAUDE.md` narrates an elaborate "March 2026"
  history and a funded $25K paper account; this is aspirational documentation, not reality.
  Treat primary evidence over `CLAUDE.md` prose.
- **Live account (read-only IBKR MCP):** `net_liquidation=5`, `total_cash=5`,
  `positions=[]`. No execution is happening.
- **Branch discrepancy (flagged):** The harness "Git Development Branch Requirements" name
  `claude/adoring-feynman-q1ox2p` as the dev branch; the scheduled task explicitly directs
  `operator/YYYY-MM-DD`. I followed the task's explicit instruction and branched
  `operator/2026-11-04` from the current HEAD (`claude/adoring-feynman-q1ox2p`, which is ahead of
  `main`). Human should confirm which branch their review tooling watches.

## Hypothesis tested

"The strategy's documented performance (CLAUDE.md: best config +6.9%/2yr) reproduces in a clean
checkout, and when compared honestly to SPY buy-and-hold over the same period, reveals whether
the strategy has a real edge." — Testable, and the honest first thing to establish.

## Actions taken

- Searched exhaustively for the mandated files; confirmed absent.
- Read live account state via IBKR MCP read-only tools.
- Pulled SPY price history (IBKR, reliable) for precise benchmark numbers.
- Installed backtest deps in the ephemeral container (`yfinance`, `loguru`, `scipy`, `pyarrow`;
  `pandas`/`numpy` were auto-upgraded to 3.1.0/2.4.6). **Not committed** — `requirements*.txt`
  untouched. Backtest engine imports and runs fine under the newer libs with ML libs absent
  (graceful degradation).
- Ran `scripts/run_walkforward_v2.py` end-to-end (3-way: Baseline / Old Filters / RDT Filters,
  6 walk-forward windows, ~510 trading days ending 2026-07-22). Raw aggregate output saved to
  `entries/2026-11-04-walkforward-v2-raw.log`.
- Bootstrapped `MANDATE.md` (v0) and this journal.

## Evidence (numbers)

Reproduced walk-forward V2 aggregate (gross of costs, $25K capital, ~510 trading days):

| Metric | A) Baseline | B) Old Filters | C) RDT Filters |
|---|---|---|---|
| Total Return | $1,605 (6.42%) | $1,573 (6.29%) | **$2,319 (9.28%)** |
| Annualized | 3.2% | 3.1% | **4.6%** |
| Win Rate | 47.2% | 47.3% | 49.5% |
| Profit Factor | 1.26 | 1.15 | 1.31 |
| Sharpe | 0.26 | — | **0.25** |
| Max Drawdown | $614 | $882 | $696 |
| Trades | 233 | 429 | 279 |

**SPY buy-and-hold benchmark (same ~2yr window, IBKR data):**
- Backtest span ≈ Jul 2024 → Jul 2026. SPY 544.22 → 762.63 = **+40.1% price (~+43% total
  return), ~18%/yr, Sharpe ~1.0+.**
- Trailing-2yr cross-check (Nov 2024 → Nov 2026): SPY 602.55 → 754.35 = **+25.2%**.
- Whatever the exact endpoints, SPY buy-and-hold returned **3–4x the strategy's best config**,
  at far higher Sharpe, with **one position and zero management.**

**Cost caveat:** `backtesting/` has no commission/slippage model. The strategy takes ~279
round-trip trades over 2 years; net of realistic costs its ~9.28% gross shrinks further, while
SPY's cost to hold is ~one trade. The gap is understated above, not overstated.

**Methodology caveat (in the strategy's favor, for fairness):** the daily-bar backtest cannot
simulate the intraday VWAP gate, first-hour filter, or intraday stops, so it is an approximation
of the real intraday strategy. But closing a 4x gap through intraday timing alone is implausible.

## Decision

- **Established the honest baseline. The strategy does not beat SPY buy-and-hold** in its own
  reproduced backtest, before costs. This is the mission's central question and the answer is no.
- I am **not declaring final wind-down on run #1** — one session, no prior journal, and the
  backtest is daily-bar only. But I am setting a clear, falsifiable bar for continuation
  (below), per the mandate's decision rules.
- **No strategy code, risk code, or config was changed.** Only journal/mandate files added.

## Escalation to the human operator

1. **The operator loop was non-functional** (no mandate, no journal). I bootstrapped a v0
   `MANDATE.md` — **please review/ratify/replace it.** It encodes only what your task prompt
   already stated.
2. **The connected IBKR account holds $5.** Fund a proper paper account, or point the operator
   at the real one, or confirm the bot is intentionally dormant. Right now there is nothing to
   make profitable in practice.
3. **The backtest has no cost model.** All historical performance claims (incl. `CLAUDE.md`'s
   tables) are gross-of-cost upper bounds. This should be fixed before any further tuning.
4. **Branch:** confirm whether review tooling watches `operator/2026-11-04` or
   `claude/adoring-feynman-q1ox2p`.

## Open questions / next-session seed

- **The bar for continuation:** produce ANY configuration that beats SPY buy-and-hold **net of
  realistic costs** in walk-forward. If no session can clear it, recommend wind-down in favor of
  holding SPY.
- **Highest-value next task:** add a realistic commission + slippage model to `backtesting/`
  (e.g. $0.005/share + N bps slippage per side) and re-baseline all three configs vs SPY. If the
  best config can't beat SPY gross, net-of-cost tuning won't close a 4x gap — so this step is
  largely confirmatory, but it makes the recommendation unimpeachable.
- Reconcile `CLAUDE.md`'s aspirational narrative with reality, or mark it clearly as a design doc.
- Confirm the intended live account and funding so "profitability" has an operational meaning.
